NFE2L2 and cancer: In many cancer cells, NRF2 has become constitutively active following the acquisition of inactivating mutations within the KEAP1 gene or missense mutations within either the KEAP1 or NRF2 gene that weaken the interaction between the two proteins[79-83] (reviewed in[84]).